placebo for risankizumab + risankizumab IV + risankizumab SC
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Crohn's Disease
Conditions
Crohn's Disease
Trial Timeline
May 10, 2017 → Apr 14, 2021
NCT ID
NCT03105128About placebo for risankizumab + risankizumab IV + risankizumab SC
placebo for risankizumab + risankizumab IV + risankizumab SC is a phase 3 stage product being developed by AbbVie for Crohn's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03105128. Target conditions include Crohn's Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03105128 | Phase 3 | Completed |
Competing Products
20 competing products in Crohn's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CT-P13 + Remicade | Celltrion | Phase 3 | 77 |
| CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 | Celltrion | Phase 1 | 33 |
| CT-P13 SC (Infliximab) | Celltrion | Phase 3 | 77 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kg | Eisai | Phase 1/2 | 41 |
| E6011 + Placebo | Eisai | Phase 2 | 52 |
| E6011 + Placebo | Eisai | Phase 1 | 33 |
| adalimumab + adalimumab + placebo | Eisai | Phase 2/3 | 65 |
| adalimumab | Eisai | Phase 2/3 | 65 |
| Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + Placebo | Eli Lilly | Phase 3 | 77 |
| Mirikizumab | Eli Lilly | Phase 3 | 77 |
| Mirikizumab + Mirikizumab + Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Mirikizumab + Placebo | Eli Lilly | Phase 2 | 52 |
| Mirikizumab | Eli Lilly | Phase 3 | 77 |
| Matching Placebo for Upadacitinib + Upadacitinib | AbbVie | Phase 3 | 77 |
| Adalimumab + Placebo | AbbVie | Phase 3 | 77 |
| Upadacitinib + Placebo for Upadacitinib | AbbVie | Phase 3 | 77 |
| Placebo + ABT-494 | AbbVie | Phase 2 | 52 |
| ABT-494 | AbbVie | Phase 2 | 52 |
| Risankizumab + Comparator | AbbVie | Pre-clinical | 23 |